ACTHIB was administered to an 11 year old patient and child was not intended to received ACTHIB and this was considered an extra dose with no adverse event; ACTHIB was administered to an 11 year old patient and child was not intended to received ACTHIB and this was considered an extra dose with no adverse event; Initial information received on 28-Jan-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves HIB (PRP/T) VACCINE [ACT-HIB] was administered to a 11 year old female patient and child was not intended to receive ACT-HIB and this was considered an extra dose with no adverse event. The patient’s past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Influenza vaccine and HPV vaccine VLP rL1 2v (baculovirus) (Human papillomavirus (types 16, 18) vaccine, adsorbed) for Immunisation. On 27-Jan-2025, the 11 year old patient received 0.5 ml (dose 3) of HIB (PRP/T) VACCINE, Powder and solvent for solution for injection (lot UK092AB; Expiration Date: 31-May-2025) via intramuscular route in the left deltoid for Immunization and child was not intended to receive ACT-HIB and this was considered an extra dose with no adverse event (product administered to patient of inappropriate age) (extra dose administered) (latency: same day). This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder’s compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.